Actively Recruiting
ROSETTA Gastric-204 Trial Comparing Pumitamig Plus Chemotherapy to Nivolumab Plus Chemotherapy for Untreated Advanced or Metastatic Gastric and Esophageal Adenocarcinoma
Led by Bristol-Myers Squibb · Updated on 2026-09-30
690
Participants Needed
161
Research Sites
96 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of Pumitamig combined with chemotherapy compared to Nivolumab combined with chemotherapy in people who have not received prior treatment for advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma. This phase 23 randomized study aims to better understand treatment options for these types of cancer. Participants will receive specified doses of Pumitamig or Nivolumab along with chemotherapy drugs such as Folfox or Capox on scheduled days. The study includes multiple experimental treatment arms and uses a double-blind method to compare these combinations. Treatment and evaluations will continue for up to several years, including a primary outcome measurement period lasting up to 2 to almost 4 years. Throughout the study, participants will undergo regular assessments to monitor tumor response, progression-free survival, overall survival, and other cancer control measures using standardized criteria like RECIST v1.1. These evaluations include investigator assessments and blinded independent reviews. Safety and dosing recommendations will also be closely monitored. Participants may expect frequent visits and follow-ups over the course of the study, which lasts several years from enrollment to outcome measurement.
CONDITIONS
Brief Title
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
F
First line of the email MUST contain NCT # and Site #.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here